Ultragenyx Pharmaceutical RARE Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's retained earnings?
- Ultragenyx Pharmaceutical (RARE) reported retained earnings of -$4.72B in Q1 2026.
- How has Ultragenyx Pharmaceutical's retained earnings changed year-over-year?
- Ultragenyx Pharmaceutical's retained earnings decreased by 14.8% year-over-year, from -$4.11B to -$4.72B.
- What is the long-term trend for Ultragenyx Pharmaceutical's retained earnings?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's retained earnings has grown at a 22.9% compound annual growth rate (CAGR), from -$1.62B to -$4.53B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.